ITeos Therapeutics Analyst Ratings
ITeos Therapeutics Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 10/18/2023 | 245.55% | Wedbush | → $33 | Reiterates | Outperform → Outperform |
| 08/09/2023 | 360.73% | HC Wainwright & Co. | $54 → $44 | Maintains | Buy |
| 03/17/2023 | 465.45% | HC Wainwright & Co. | → $54 | Reiterates | → Buy |
| 03/16/2023 | 235.08% | JP Morgan | $34 → $32 | Maintains | Overweight |
| 03/16/2023 | 245.55% | Wedbush | $45 → $33 | Maintains | Outperform |
| 05/13/2022 | 517.8% | SVB Leerink | $60 → $59 | Maintains | Outperform |
| 12/13/2021 | 465.45% | HC Wainwright & Co. | $37 → $54 | Maintains | Buy |
| 11/12/2021 | 465.45% | SVB Leerink | $55 → $54 | Maintains | Outperform |
| 08/13/2021 | 475.92% | SVB Leerink | $56 → $55 | Maintains | Outperform |
| 05/19/2021 | 371.2% | SVB Leerink | $60 → $45 | Maintains | Outperform |
| 05/05/2021 | 287.43% | HC Wainwright & Co. | → $37 | Initiates Coverage On | → Buy |
| 04/06/2021 | 528.27% | SVB Leerink | $37 → $60 | Maintains | Outperform |
| 11/19/2020 | 287.43% | SVB Leerink | $36 → $37 | Maintains | Outperform |
| 10/08/2020 | 371.2% | Baird | → $45 | Initiates Coverage On | → Outperform |
| 08/18/2020 | 318.85% | JP Morgan | → $40 | Initiates Coverage On | → Overweight |
| 08/18/2020 | 371.2% | Wedbush | → $45 | Initiates Coverage On | → Outperform |
| 08/18/2020 | 276.96% | SVB Leerink | → $36 | Initiates Coverage On | → Outperform |
| 08/18/2020 | 423.56% | Piper Sandler | → $50 | Initiates Coverage On | → Overweight |
| 日期 | 上行/下行 | 分析公司 | 目标价格变化 | 评级变化 | 上一次/当前评级 |
|---|---|---|---|---|---|
| 10/18/2023 | 245.55% | 韦德布什 | →$33 | 重申 | 跑赢→跑赢大盘 |
| 08/09/2023 | 360.73% | HC Wainwright公司 | $54→$44 | 维护 | 买 |
| 03/17/2023 | 465.45% | HC Wainwright公司 | →$54 | 重申 | →购买 |
| 03/16/2023 | 235.08% | 摩根大通 | $34→$32 | 维护 | 超重 |
| 03/16/2023 | 245.55% | 韦德布什 | $45→$33 | 维护 | 跑赢大盘 |
| 2022年05月13日 | 517.8% | SVB Leerink | $60→$59 | 维护 | 跑赢大盘 |
| 2021年12月13日 | 465.45% | HC Wainwright公司 | $37→$54 | 维护 | 买 |
| 2021年11月12日 | 465.45% | SVB Leerink | $55→$54 | 维护 | 跑赢大盘 |
| 2021/08/13 | 475.92% | SVB Leerink | $56→$55 | 维护 | 跑赢大盘 |
| 2021/05/19 | 371.2% | SVB Leerink | $60→$45 | 维护 | 跑赢大盘 |
| 05/05/2021 | 287.43% | HC Wainwright公司 | →$37 | 开始承保 | →购买 |
| 04/06/2021 | 528.27% | SVB Leerink | $37→$60 | 维护 | 跑赢大盘 |
| 11/19/2020 | 287.43% | SVB Leerink | $36→$37 | 维护 | 跑赢大盘 |
| 10/08/2020 | 371.2% | 贝尔德 | →$45 | 开始承保 | →跑赢大盘 |
| 2020/08/18 | 318.85% | 摩根大通 | →$40 | 开始承保 | →超重 |
| 2020/08/18 | 371.2% | 韦德布什 | →$45 | 开始承保 | →跑赢大盘 |
| 2020/08/18 | 276.96% | SVB Leerink | →$36 | 开始承保 | →跑赢大盘 |
| 2020/08/18 | 423.56% | 派珀·桑德勒 | →$50 | 开始承保 | →超重 |
What is the target price for ITeos Therapeutics (ITOS)?
ITeos治疗公司(ITOS)的目标价格是多少？
The latest price target for ITeos Therapeutics (NASDAQ: ITOS) was reported by Wedbush on October 18, 2023. The analyst firm set a price target for $33.00 expecting ITOS to rise to within 12 months (a possible 245.55% upside). 5 analyst firms have reported ratings in the last year.
韦德布什于2023年10月18日报道了iTeos治疗公司(纳斯达克：ITOS)的最新目标价。这家分析公司将目标价定为33美元，预计Itos将在12个月内上涨(可能上涨245.55%)。去年有5家分析公司公布了评级。
What is the most recent analyst rating for ITeos Therapeutics (ITOS)?
ITeos治疗公司(ITOS)的最新分析师评级是多少？
The latest analyst rating for ITeos Therapeutics (NASDAQ: ITOS) was provided by Wedbush, and ITeos Therapeutics reiterated their outperform rating.
对iTeos治疗公司(纳斯达克代码：ITOS)的最新分析师评级是由韦德布什公司提供的，iTeos治疗公司重申了他们的表现优于大盘的评级。
When is the next analyst rating going to be posted or updated for ITeos Therapeutics (ITOS)?
ITeos治疗公司(ITOS)的下一次分析师评级将于何时发布或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of ITeos Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for ITeos Therapeutics was filed on October 18, 2023 so you should expect the next rating to be made available sometime around October 18, 2024.
分析师在进行了广泛的研究后得出股票评级，其中包括查阅公共财务报表，与iTeos治疗公司的高管和客户交谈，以及听取收益电话会议。大多数分析师每三个月就会这样做一次，所以你每年应该会得到每家公司每家公司的4个评级。ITeos治疗公司的上一次评级是在2023年10月18日提交的，所以你应该预计下一次评级将在2024年10月18日左右的某个时候提供。
Is the Analyst Rating ITeos Therapeutics (ITOS) correct?
分析师对ITOS Treateutics(ITOS)的评级正确吗？
While ratings are subjective and will change, the latest ITeos Therapeutics (ITOS) rating was a reiterated with a price target of $0.00 to $33.00. The current price ITeos Therapeutics (ITOS) is trading at is $9.55, which is within the analyst's predicted range.
虽然评级是主观的，并将发生变化，但最新的iTeos治疗公司(ITOS)评级被重申，目标价在0.00美元至33.00美元之间。目前iTeos治疗公司(ITOS)的交易价格为9.55美元，在分析师的预测范围内。